Scanni A, Tomirotti M, Licciardello L, Annibali E, Biraghi M, Trovato M, Fittipaldi M, Adamoli P, Curtarelli G
Tumori. 1979 Jun 30;65(3):331-8. doi: 10.1177/030089167906500308.
Serum copper and ceruloplasmin levels (SCL, SCeL) in 57 patients with advanced cancer of the stomach (35 cases) or large intestine (22 cases) treated with polychemotherapy were studies. In gastroenteric cancer, SCL, which are already high in untreated patients, have a tendency to increase further in cases of progression of the disease, while they seem to significantly decrease in cases of remission. SCeL during the trial appeared to be correlated to the clinical evolution of the disease only in the case of stomach cancer. In large intestine cancer, SCeL did not show any significant variation in relation to the normal range. These observations, in particular on the behavior of SCL in the neoplasms of the digestive tract, are in accordance with the results of other studies. The authors are inclined to attach a diagnostic and prognostic value to the variation in SCL and SCeL in gastrointestinal cancer.
对57例接受多药化疗的晚期胃癌（35例）或大肠癌（22例）患者的血清铜和铜蓝蛋白水平（SCL，SCeL）进行了研究。在胃肠道癌中，未经治疗的患者SCL就已很高，疾病进展时SCL有进一步升高的趋势，而缓解时则似乎显著降低。试验期间，SCeL似乎仅在胃癌病例中与疾病的临床进展相关。在大肠癌中，SCeL相对于正常范围未显示出任何显著变化。这些观察结果，尤其是关于SCL在消化道肿瘤中的表现，与其他研究结果一致。作者倾向于认为SCL和SCeL的变化对胃肠道癌具有诊断和预后价值。
